Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 14:18 ET | Source: Faruqi & Faruqi LLP

ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or...
April 02, 2026 14:05 ET | Source: Beyond Prostate

Empower Health Labs Beyond Prostate Under Investigation: Researching the Scientific Benefits of Each Ingredient & Official Website Claims

2026 report on Beyond Prostate ingredients, saw palmetto research, dosage disclosure, refund terms, and consumer verification steps.
April 02, 2026 13:38 ET | Source: Glancy Prongay Wolke & Rotter LLP

Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action...
April 02, 2026 13:00 ET | Source: DelveInsight Business Research LLP

The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight

New York, USA, April 02, 2026 (GLOBE NEWSWIRE) -- The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight The SCI treatment pipeline continues to expand,...
April 02, 2026 12:30 ET | Source: GENFIT S.A.

GENFIT : Résultats financiers annuels 2025 et point sur les activités de la Société

Faits financiers marquants de 2025 : Trésorerie et équivalents de trésorerie s’élevant à 101.1 millions d’euros au 31 décembre 2025 Chiffre d’affaires s’élevant à 65.4 millions d’euros au 31 décembre...
April 02, 2026 12:30 ET | Source: GENFIT S.A.

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

2025 financial highlights: Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million...
April 02, 2026 12:08 ET | Source: The Law Offices of Frank R. Cruz

DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
April 02, 2026 12:00 ET | Source: Bronstein, Gewirtz & Grossman, LLC

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Atara (ATRA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/22/2026.
April 02, 2026 12:00 ET | Source: Bronstein, Gewirtz & Grossman, LLC

Bronstein, Gewirtz & Grossman LLC Urges Inovio Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Inovio (INO) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/7/2026.
April 02, 2026 12:00 ET | Source: Regeneron Pharmaceuticals, Inc.

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing...